Monoclonal antibodies such as vascular endothelial growth factor inhibitors (VEGFi) and rituximab (anti‐CD20) have been associated with coronary syndromes, thought to be driven by a direct endothelial damage leading to ischemia and thus contribute to ventricular dysfunction [11]. The gene discussed is VEGFA; the disease is ischemia.